Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Thyroid cancer
Stage/Subtype:  anaplastic thyroid cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-10 of 10 for your search:
Start Over
Sapanisertib in Treating Patients with Newly Diagnosed or Refractory/Metastatic Anaplastic Thyroid Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-223, NCI-2015-01607, NCT02244463
A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PLX120-03, NCI-2015-00720, NCT02428712
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117019, NCI-2014-00802, NCT02034110
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients with Advanced Anaplastic Thyroid Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: A091305, NCI-2014-00686, NCT02152137
Ceritinib in Treating Patients with Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 082014-029, NCI-2014-02360, NCT02289144
Pembrolizumab in Treating Patients with Rare Tumors That Cannot Be Removed by Surgery or are Metastatic
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0948, NCI-2016-00545, NCT02721732
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: E7080-M000-213, NCI-2016-01668, NCT02657369
Pembrolizumab in Treating Patients with Metastatic or Locally Advanced Thyroid Gland Undifferentiated (Anaplastic) Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: STU 012016-019, NCI-2016-01726, NCT02688608
PI3K/HDAC Inhibitor CUDC-907 in Treating Patients with Locally Advanced or Metastatic Thyroid Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 17-C-0029, NCI-2016-02012, NCT03002623
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CFAZ053X2101, NCI-2017-00042, 2016-001470-15, NCT02936102
Start Over